Shield Therapeutics (STX)

Company name:Shield Therapeutics Plc
EPIC:STXTrading Currency:GBX
Market Sector:AMQ1ISIN:GB00BYV81293
Market Segment:ASQ1Share Type:DE
WWW Address: 1.5P
 Price Price Change [%] Bid Offer Open High Low Volume
 51.50 1.0 [1.98] 50.00 53.00 50.50 51.50 50.00 337,780
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 111.16 215.84 0.00 -8.00 - - - 150.00 - 32.50

Shield Therapeutics Key Figures

(at previous day's close)
Market Cap.111.16m
Shares In Issue215.84m
Prev. Close50.50
PE Ratio- 
Dividend Yield-%
EPS - basic-8.00p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-1.88p
Return On Equity (ROE)-27.38%
Operating Margin-1,260.92%
PEG Factor- 
EPS Growth Rate-300.00%
Dividends PS Growth Rate-%
Net Debt0.03m
Gross Gearing11.49%
Quick Assets5.45m
Net Working Capital2.22m
Intangibles / Fixed Assets99.91%
Turnover PS0.33p
Pre-Tax Profit PS-4.20p
Retained Profit PS-4.08p
Cash PS1.92p
Net Cash PS-0.02p
Net Tangible Asset Value PS *1.04p
Net Asset Value PS14.89p
Spread3.00 (5.66%) 

Shield Therapeutics Balance Sheet


Share Price Performance

Sample Period HighLow
1 week52.0042.50
4 weeks52.0040.50
12 weeks61.5040.50
1 year150.0032.50

Share Price Chart (5 years)

Shield Therapeutics Historic Returns

Period OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week43.008.5019.7742.500.4947.35
4 weeks50.501.001.9840.500.6445.09
12 weeks52.50-1.00-1.9040.501.1954.26
26 weeks52.50-1.00-1.9032.501.5245.60
1 year91.00-39.50-43.4132.501.0252.11
3 years34.5017.0049.2828.500.5064.66
5 years157.50-106.00-67.3013.000.3862.92

Shield Therapeutics Key Management Ratios

Shield Therapeutics Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio- 
Tobin's Q Ratio 2.79 
Tobin's Q Ratio (excl. intangibles)11.80 
Dividend Yield-%
Market-to-Book Ratio3.46 
Price-to-Pre-Tax Profit PS-12.26 
Price-to-Retained Profit PS-12.63 
Price-to-Cash Flow PS-27.34 
Price-to-Sales PS154.60 
Price-to-Net Tangible Asset Value PS49.47 
Price-to-Cash PS26.84 
Net Working Capital PS1.03 
Price Pct to Working Capital PS50.05%
Earnings Yield-%
Average PE- 
Years in average- 
PE to PE average-%

Shield Therapeutics Financial Ratios

(Leverage Ratios)
Debt Ratio-%
Debt-to-Equity Ratio- 
Debt-to-Equity Ratio (excl. Intgbl)- 
Debt-to-Equity Market Value- 
Net Gearing0.09%
Net Gearing (excl. Intangibles)0.51%
Gross Gearing11.49%
Gross Gearing (excl. Intangibles)65.01%
Gearing Under 1 Year11.49%
Gearing Under 1 Year (excl. Intgbl)65.01%
(Liquidity Ratios)
Net Working Capital to Total Assets6.12%
Current Ratio1.53 
Quick Ratio (Acid Test)1.30 
Liquidity Ratio0.99 
Cash & Equiv/Current Assets64.75%
(Solvency Ratios)
Enterprise Value107.02m
CFO/Attributable Profit- 
Total Debt/Equity Market Value0.04 
Total Debt/Sales5.81 
Total Debt/Pre-Tax Profit-0.46 
Total Debt4.17m
Total Debt/Net Current Assets1.88%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-22.22%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs3 
Beta (60-Mnth)Beta (36-Mnth)

Shield Therapeutics Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)-28.20%
Return On Assets (ROA)-22.08%
Net Profit Margin-1,223.92%
Assets Turnover0.02 
Return On Equity (ROE)-27.38%
Return On Investment (ROI)-24.25%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio-%
Net Income Of Revenues-1,223.92%
(Asset Utilisation Multiples)
Shareholders Equity Turnover0.02 
Fixed Assets Turnover0.02 
Current Assets Turnover0.08 
Net Working Capital Turnover 
Inventory Turnover1.36 
(Other Operating Ratios)
Total Assets-to-Sales55.42 
Debt Collection Period973.93Days

Shield Therapeutics Dividends

Sorry No Data Available

Shield Therapeutics Fundamentals

 31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)
pre tax profit-15.60--20.99--5.15-43.37%-9.07-m
attributable profit-15.02--19.59--1.79-15.10%-8.80-m
retained profit-15.02--19.59--1.79-15.10%-8.80-m
eps - basic (p)-15.00 -17.00 -2.00 -8.00 
eps - diluted (p)-15.00 -17.00 -2.00 -8.00 
dividends per share- - - - 

Shield Therapeutics Balance Sheet

 31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)
 31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)
fixed assets fixed assets0.020.04%0.010.03%0.010.02%0.030.07%m
intangibles intangibles28.9855.33%29.9666.62%30.9671.36%29.9082.32%m
fixed investments fixed investments--%--%--%--%m
current assets - other current assets - other--%--%--%--%m
stocks stocks0.420.80%0.130.28%0.110.25%0.952.61%m
debtors debtors1.993.79%1.573.50%2.535.83%1.313.60%m
cash & securities cash & securities20.9840.05%13.3029.57%9.7822.54%4.1411.40%m
creditors - short creditors - short3.997.61%3.768.37%2.956.80%4.1711.49%m
creditors - long creditors - long--%--%--%--%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
ord cap, reserves ord cap, reserves48.4092.39%41.2191.63%40.4393.20%32.1588.51%m
prefs, minorities prefs, minorities--%--%--%--%m
NAV Basic- - - - 
NAV Diluted- - - - 

Shield Therapeutics Cash Flow Statement

31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)31 Dec 2019 (GBP)
Operating CF-10.26-16.15-0.18-4.07m
Pre-Financing CF-13.25-19.56-3.52-5.43m
Retained CF20.25-7.68-3.52-5.64m

Shield Therapeutics Brokers

Broker infomation is not available for this class of stock.
ADVFN Advertorial
Your Recent History
Shield The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210805 11:09:06